VenomAid is dedicated to transforming snakebite care through innovative technologies that focus on antibody discovery and venomics. The company is developing advanced diagnostic tools, including a novel monoclonal antibody-based lateral flow assay that can rapidly detect Bothrops and Lachesis venoms in clinical samples. This assay provides results within 15 minutes and is designed for point-of-care use, significantly enhancing diagnostic precision and patient outcomes. By making these diagnostics affordable and accessible, VenomAid aims to empower healthcare professionals in managing snakebite cases effectively, particularly in regions that have been historically underserved.

In addition to its diagnostic innovations, VenomAid emphasizes the importance of education and awareness in addressing the global burden of snakebites. The company collaborates with various health organizations and educational institutions to promote understanding of snakebite envenoming and the role of antibodies in both diagnosis and treatment. Through initiatives like the "Fight the Bite" educational project, VenomAid seeks to engage students and communities in the science of snakebite care, fostering a more informed approach to this neglected tropical disease. Overall, VenomAid's commitment to combining cutting-edge science with community engagement positions it as a leader in the field of snakebite care.

Denmark

VenomAid Diagnostics is a young, impact-oriented medtech start-up developing affordable, easy-to-use, and robust diagnostics enabling best-in-class snakebite management worldwide, ultimately reducing the global burden of snakebite. 

Snakebite is a global problem affecting millions of people worldwide, most severely in low- and middle-income countries. The only effective treatment, specific antivenom, is scarcely available and can only be given if the perpetrating snake is known. 

VenomAid

Company Details